.
MYD financial statements
* Numbers in millions
Year |
2020 | TTM |
|---|---|---|
Capitalization * |
706 | 1 761 |
EV * |
821 | 821 |
Stock price € |
9.5 | 23.7 |
Number of shares * |
74 | 74 |
EPS |
-2,69 | -2,69 |
Revenue * |
639 | 639 |
Net income * |
-200 | -200 |
Operating profit * |
-135 | -135 |
Total liabilities * |
486 | 486 |
Net debt * |
115 | 115 |
Total assets * |
1 405 | 1 405 |
Equity * |
918 | 918 |
Cash and investments * |
218 | 218 |
Over the past 10 years, the maximum capitalization of Myriad Genetics, Inc. is 706, the minimum is 706. Maximum net income 0, Minimum net income -200. The maximum price of MYD shares is 9.5, the minimum price is 9.5.
.
MYD valuation
Year |
2020 | TTM |
|---|---|---|
P/E |
-3,54 | -8,83 |
P/B |
0,77 | 1,92 |
P/S |
1,11 | 2,76 |
E/P |
-28% | -11% |
P/FCF |
13,98 | 34,87 |
.
MYD profitability
Year |
2020 | TTM |
|---|---|---|
ROE |
-22% | |
ROA |
-42% | |
ROIC |
-11% |